With roughly 3% of the UK suffering from psoriasis, one doctor is raising the alarm on the earliest warning signs that give patients the best chance of coping ...

Patients with psoriasis have a higher risk for synovitis on imaging than healthy individuals, according to a systematic ...

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

If psoriasis runs in your family, you may carry the genes—but lifestyle choices and early care can make all the difference in ...

Chronic skin conditions like psoriasis can get more severe in midlife. It's not impossible to deal with them, though.

Early intervention with IL-17 inhibitors among patients with plaque psoriasis is associated with improved relapse and remission rates.

Improvements in Scalp Itch-Numeric Rating Scale (SI-NRS) were greater in the roflumilast group than for the vehicle group, with a statistically significant difference as early as 24 hours (-0.44 ...

Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3%, which is now available for treating plaque psoriasis on the scalp and body in patients aged 12 and ...

Icotrokinra demonstrated high rates of skin clearance in patients with scalp psoriasis as 66% achieved a scalp-specific Investigator's Global Assessment (ss-IGA) c score of 0/1 compared to 11% ...

Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body psoriasis, according to a study published in JAMA Dermatology. According to ...

Researchers evaluated outcomes in a cohort of patients in the phase 3b randomized VISIBLE trial, which included 102 adults with skin of color and scalp psoriasis (mean age, 42.5 years; Fitzpatrick ...